KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $11.6 million.

  • Emergent BioSolutions' Other Non-Current Assets rose 7846.15% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 7846.15%. This contributed to the annual value of $18.9 million for FY2024, which is 9027.28% down from last year.
  • Per Emergent BioSolutions' latest filing, its Other Non-Current Assets stood at $11.6 million for Q3 2025, which was up 7846.15% from $12.5 million recorded in Q2 2025.
  • Emergent BioSolutions' Other Non-Current Assets' 5-year high stood at $194.3 million during Q4 2023, with a 5-year trough of $500000.0 in Q1 2024.
  • In the last 5 years, Emergent BioSolutions' Other Non-Current Assets had a median value of $40.8 million in 2022 and averaged $52.6 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first crashed by 9027.28% in 2024, then surged by 252000.0% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Other Non-Current Assets (Quarter) stood at $58.2 million in 2021, then decreased by 29.9% to $40.8 million in 2022, then skyrocketed by 376.23% to $194.3 million in 2023, then plummeted by 90.27% to $18.9 million in 2024, then plummeted by 38.62% to $11.6 million in 2025.
  • Its last three reported values are $11.6 million in Q3 2025, $12.5 million for Q2 2025, and $13.1 million during Q1 2025.